SEC Form SC 13G filed by Myovant Sciences Ltd.
$MYOV
Biotechnology: Pharmaceutical Preparations
Health Care
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
|
MYOVANT SCIENCES LTD.
|
|
(Name of Issuer)
|
|
Common shares, $0.000017727 par value per share
|
|
(Title of Class of Securities)
|
|
G637AM102
|
|
(CUSIP Number)
|
|
February 8, 2023
|
|
(Date of Event which Requires Filing of this Statement)
|
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
[_] Rule 13d-1(b)
[X] Rule 13d-1(c)
[_] Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities,
and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act
of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
SCHEDULE 13G
|
CUSIP No.
|
G637AM102
|
|
1
|
Names of Reporting Persons
|
||
|
Alpine Global Management, LLC1
|
|||
|
2
|
Check the appropriate box if a member of a Group (see instructions)
|
||
|
(a) [ ]
(b) [X] |
|||
|
3
|
Sec Use Only
|
||
|
4
|
Citizenship or Place of Organization
|
||
|
Delaware, USA
|
|||
|
Number of
Shares
Beneficially
Owned
by Each
Reporting
Person
With:
|
5
|
Sole Voting Power
|
|
|
6,425,084
|
|||
|
6
|
Shared Voting Power
|
||
|
0
|
|||
|
7
|
Sole Dispositive Power
|
||
|
6,425,084
|
|||
|
8
|
Shared Dispositive Power
|
||
|
0
|
|||
|
9
|
Aggregate Amount Beneficially Owned by Each Reporting Person
|
||
|
6,425,084
|
|||
|
10
|
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
|
||
|
[ ]
|
|||
|
11
|
Percent of class represented by amount in row (9)
|
||
|
6.6%2
|
|||
|
12
|
Type of Reporting Person (See Instructions)
|
||
|
OO, Other (Limited Liability Company)
|
|||
1 In addition to Alpine Global Management, LLC, Alpine Partners (BVI),
L.P. also owns the shares indirectly and is a beneficial owner.
2 As of February 8, 2023, Alpine Global Management, LLC held directly and Alpine Partners
(BVI), L.P. held indirectly 5.7% shares of common stock. Based on purchases since February 8, 2023, the Applicants hold 6,425,084 shares as of the date of this filing.
Item 1.
(a) Name of Issuer:
Myovant Sciences Ltd.
(b) Address of Issuer’s Principal Executive Offices:
7th Floor, 50 Broadway, London SW1H 0DB, United Kingdom
Item 2.
|
(a)
|
Name of Person Filing:
|
Alpine Global Management LLC
|
(b)
|
Address of Principal Business Office or, if None, Residence:
|
140 Broadway, 38th Floor
New York, NY 10005
|
(c)
|
Citizenship:
|
Delaware, USA
|
(d)
|
Title and Class of Securities:
|
Common shares, $0.000017727 par value per share
|
(e)
|
CUSIP No.: G637AM102
|
| Item 3. |
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
|
| (a) | [_] | Broker or dealer registered under Section 15 of the Act; |
| (b) | [_] | Bank as defined in Section 3(a)(6) of the Act; |
| (c) | [_] | Insurance company as defined in Section 3(a)(19) of the Act; |
| (d) | [_] | Investment company registered under Section 8 of the Investment Company Act of 1940; |
| (e) | [_] | An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); |
| (f) | [_] | An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); |
| (g) | [_] | A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G); |
| (h) | [_] | A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); |
| (i) | [_] | A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940; |
| (j) | [_] | A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J); |
| (k) | [_] | Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: |
Item 4. Ownership
|
(a)
|
Amount Beneficially Owned:
|
6,425,084
(b) Percent of Class:
6.6% Based upon 97,235,316 shares of the registrant’s common shares, par value $0.000017727 per share, as reported by
Myovant Sciences Ltd. in its Form 10-Q filed on January 26, 2023.
(c) Number of shares as to which such person has:
(i) Sole power to vote or to direct the vote:
6,425,084
(ii) Shared power to vote or to direct the vote:
0
|
(iii)
|
Sole power to dispose or to direct the disposition of:
|
6,425,084
|
(iv)
|
Shared power to dispose or to direct the disposition of:
|
0
Item 5. Ownership of Five Percent or Less of a Class.
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be
the beneficial owner of more than five percent of the class of securities, check the following [ ].
| Item 6. |
Ownership of more than Five Percent on Behalf of Another Person.
|
N/A
| Item 7. |
Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person.
|
N/A
| Item 8. |
Identification and classification of members of the group.
|
N/A
Item 9. Notice of Dissolution of Group.
N/A
| Item 10. |
Certifications.
|
By signing below, I certify that, to the best of my knowledge and belief, the securities referred
to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction
having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true,
complete and correct.
Dated: February 17, 2023
/s/ Amy Tarlowe
Name: Amy Tarlowe
Title: Chief Operating Officer
The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the
statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of this filing person), evidence of the representative's authority to sign on behalf of such person shall be filed with the
statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath
his signature.
Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C.
1001).